Zynerba Pharmaceuticals, Inc. (ZYNE)

Market Cap	20.30M
Revenue (ttm)	n/a
Net Income (ttm)	-35.04M
Shares Out	47.06M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,079
Open	0.430
Previous Close	0.440
Day's Range	0.413 - 0.440
52-Week Range	0.390 - 2.150
Beta	1.74
Analysts	Buy
Price Target	5.55 (+1,221.11%)
Earnings Date	May 15, 2023

About ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is h...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Aug 5, 2015
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: ZYNE

Analyst Forecast

According to 10 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is $5.55, which is an increase of 1,221.11% from the latest price.

Price Target

$5.55

(1,221.11% upside)

Analyst Consensus: Buy